Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for DGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 597.00M
March 31, 2026 278.00M
December 31, 2025 465.00M
September 30, 2025 563.00M
June 30, 2025 544.00M
March 31, 2025 314.00M
December 31, 2024 464.00M
September 30, 2024 356.00M
June 30, 2024 360.00M
March 31, 2024 154.00M
December 31, 2023 527.00M
September 30, 2023 207.00M
June 30, 2023 444.00M
March 31, 2023 94.00M
December 31, 2022 334.00M
September 30, 2022 502.00M
June 30, 2022 402.00M
March 31, 2022 480.00M
December 31, 2021 481.00M
September 30, 2021 561.00M
June 30, 2021 460.00M
March 31, 2021 731.00M
December 31, 2020 541.00M
September 30, 2020 862.00M
June 30, 2020 355.00M
Date Value
March 31, 2020 247.00M
December 31, 2019 348.00M
September 30, 2019 299.00M
June 30, 2019 321.00M
March 31, 2019 275.00M
December 31, 2018 295.00M
September 30, 2018 402.00M
June 30, 2018 323.00M
March 31, 2018 180.00M
December 31, 2017 323.00M
September 30, 2017 362.00M
June 30, 2017 294.00M
March 31, 2017 196.00M
December 31, 2016 304.00M
September 30, 2016 301.00M
June 30, 2016 311.00M
March 31, 2016 153.00M
December 31, 2015 271.00M
September 30, 2015 212.00M
June 30, 2015 275.00M
March 31, 2015 52.00M
December 31, 2014 303.00M
September 30, 2014 271.00M
June 30, 2014 280.00M
March 31, 2014 84.00M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Labcorp Holdings, Inc. 445.50M
DaVita, Inc. 490.07M
OPKO Health, Inc. -43.50M
Psychemedics Corp. --
NeoGenomics, Inc. 19.96M